Citations

Showing 10 of 108094 citations.

Machine Learning-Based Fragment Selection Improves the Performance of Qualitative PRM Assays
Vanderboom, Patrick M. , Maus, Anthony , Kemp, Jennifer, Gurtner, Kari M., Grebe, Stefan K. , Pandey, Akhilesh , Dasari, Surendra , Renuse, Santosh , Maus, Anthony D , Madugundu, Anil K. , Kemp, Jennifer V, Pandey, Akhilesh , Singh, Ravinder J.

Mayo Clinic

Journal of Proteome Research | July 18, 2022 | Volume: 21 | Issue: 8 | Pages: 2045-2054

10.1021/acs.jproteome.2c00156 | PMID 35849720 Get It

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
Khurana, Arushi , Mwangi, Raphael , Link, Brian K. , Wang, Yucai , Feldman, Andrew L. , Thompson, Carrie A. , Novak, Anne J. , Villasboas, José C. , Thanarajasingam, Gita , Farooq, Umar , Syrbu, Sergei , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Link, Brian K , Wang, Yucai , Feldman, Andrew L , Novak, Anne J , Villasboas, Jose Caetano , Farooq, Umar , Witzig, T.E. , Cerhan, James R , Maurer, Matthew , Syrbu, Sergei , Tun, Aung M. , Witzig, Thomas E. , Rimsza, Lisa M. , Cerhan, James R. , Habermann, Thomas M. , Maurer, Matthew J.

Mayo Clinic

Blood Advances | July 18, 2022 | Volume: 6 | Issue: 17 | Pages: 5210-5221

10.1182/bloodadvances.2022007990 | PMID 35849723 Get It

Abstract Low-grade B-cell lymphomas other than follicular and small lymphocytic lymphoma (LGBCL) account for 10% of all B-cell non-Hodgkin lymphomas. Despite improvements in survival outcomes for these patients, little is known about cause of death (COD) in the rituximab era. For a better understanding, we studied 822 newly diagnosed patients with marginal zone, lymphoplasmacytic, and unclassifiable low-grade B-cell lymphoma prospectively enrolled in the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource from 2002 to 2015. COD was assigned based on medical record review using a standard protocol. At a median follow-up of 107 months, 219 (27%) patients had died. The incidence of lymphoma-related deaths when pooling across subtypes was lower than non–lymphoma-related deaths (10-year incidence, 8.0%; 95% confidence interval [CI]: 6.2-10.4 vs 13.6%; 95% CI: 11.2-16.6). The incidence of lymphoma-related deaths varied by subtype, ranging from 3.7% at 10 years in extranodal marginal zone lymphoma to 19.3% in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Patients with early progression or retreatment events, defined using event-free survival at 24 months from diagnosis, had significantly higher likelihood of lymphoma-related death compared with patients without early events (10-year estimate: 19.1% vs 5.1%, respectively; P < .001), whereas the rates for non–lymphoma-related death were comparable in patients with or without early events (10-year estimates: 11.0% vs 15.3%, respectively). In conclusion, the most common COD in LGBCLs in the first decade after diagnosis was for causes other than lymphoma. Progression or retreatment within the first 2 years of diagnosis was a strong predictor for risk of lymphoma-related death.
Leaving the Social Vacuum: Expanding Cardiovascular Guidelines to Embrace Equity
Magnani, Jared W. , Brewer, LaPrincess C. , Magnani, Jared W , Brewer, LaPrincess C

Mayo Clinic

Circulation | July 18, 2022 | Volume: 146 | Issue: 3 | Pages: 156-158

10.1161/circulationaha.122.060881 | PMID 35861768 Get It

Community-Based, Cluster-Randomized Pilot Trial of a Cardiovascular Mobile Health Intervention: Preliminary Findings of the FAITH! Trial
Brewer, LaPrincess C. , Jenkins, Sarah M. , Hayes, Sharonne N. , Kumbamu, Ashok , Patten, Christi A. , Hayes, Sharonne N , Brewer, LaPrincess C , Jones, Clarence , Burke, Lora E. , Cooper, Lisa A.

Mayo Clinic

Circulation | July 18, 2022 | Volume: 146 | Issue: 3 | Pages: 175-190

10.1161/circulationaha.122.059046 | PMID 35861762 Get It

Background: African Americans continue to have suboptimal cardiovascular health (CVH) based on the American Heart Association Life’s Simple 7 (LS7), 7 health-promoting behaviors and biological risk factors (eg, physical activity, blood pressure). Innovative, community-level interventions in partnership with trusted institutions such as African American churches are potential means to improve CVH in this population. Methods: Using a community-based participatory research approach, the FAITH! Trial (Fostering African American Improvement in Total Health) rigorously assessed the feasibility and preliminary efficacy of a refined, community-informed, mobile health intervention (FAITH! App) for promoting CVH among African Americans in faith communities using a cluster randomized controlled trial. Participants from 16 churches in Rochester and Minneapolis-St Paul, MN, were randomized to receive the FAITH! App (immediate intervention) or were assigned to a delayed intervention comparator group. The 10-week intervention core features included culturally relevant and LS7-focused education modules, diet/physical activity self-monitoring, and a group sharing board. Data were collected via electronic surveys and health assessments. Primary outcomes were average change in mean LS7 score (continuous measure of CVH ranging from poor to ideal [0–14 points]) from baseline to 6 months post-intervention (using generalized estimating equations) and app engagement/usability (by the Health Information Technology Usability Evaluation Scale; range, 0–5). Results: Of 85 enrolled participants (randomized to immediate [N=41] and delayed [control] intervention [N=44] groups), 76 and 68 completed surveys/health assessments at baseline and 6 months post-intervention, respectively (80% retention rate with assessments at both baseline and 6-month time points); immediate intervention [N=30] and control [N=38] groups). At baseline, the majority of participants (mean age [SD], 54.2 [12.3] years, 71% female) had <4-year college education level (39/66, 59%) and poor CVH (44% in poor category; mean LS7 score [SD], 6.8 [1.9]). The mean LS7 score of the intervention group increased by 1.9 (SD 1.9) points compared with 0.7 (SD 1.7) point in the control group (both P <0.0001) at 6 months. The estimated difference of this increase between the groups was 1.1 (95% CI, 0.6–1.7; P <0.0001). App engagement/usability was overall high (100% connection to app; >75% completed weekly diet/physical activity tracking; Health Information Technology Usability Evaluation Scale, mean [SD], 4.2 [0.7]). Conclusions: On the basis of preliminary findings, the refined FAITH! App appears to be an efficacious mobile health tool to promote ideal CVH among African Americans. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03777709.
Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia
Daver, Naval , Perl, Alexander E. , Maly, Joseph, Ritchie, Ellen K. , Litzow, Mark R. , McCloskey, James, Smith, Catherine C. , Schiller, Gary J. , Bradley, Terrence, Tiu, Ramón V., Naqvi, Kiran , Brackman, Deanna J. , Siddani, Satya R., Wang, Jing , Chyla, Brenda , Lee, Paul , Altman, Jessica K. , Litzow, Mark R. , Smith, Catherine C , Dail, Monique , Chyla, Brenda , Altman, Jessica K , Daver, Naval , Levis, Mark J. , Dail, Monique

Mayo Clinic

Journal of Clinical Oncology | July 18, 2022 | Volume: 40 | Issue: 35 | Pages: 4048-4059

10.1200/jco.22.00602 | PMID 35849791 Get It

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated ( FLT3 mut ) acute myeloid leukemia (AML) but seldom reduces FLT3 mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3 mut AML. METHODS This phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505 ) enrolled patients with FLT3 wild-type and FLT3 mut (escalation) or FLT3 mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III–defined response criteria. RESULTS Sixty-one patients were enrolled (n = 56 FLT3 mut ); 64% (n = 36 of 56) of FLT3 mut patients had received prior FLT3 inhibitor therapy. The recommended phase II dose was 400 mg venetoclax once daily and 120 mg gilteritinib once daily. The most common grade 3/4 adverse events were cytopenias (n = 49; 80%). Adverse events prompted venetoclax and gilteritinib dose interruptions in 51% and 48%, respectively. The mCRc rate for FLT3 mut patients was 75% (CR, 18%; CR with incomplete blood count recovery, 4%; CR with incomplete platelet recovery, 18%; and morphologic leukemia-free state, 36%) and was similar among patients with or without prior FLT3 inhibitor therapy (80% v 67%, respectively). The median follow-up was 17.5 months. The median time to response was 0.9 months, and the median remission duration was 4.9 months (95% CI, 3.4 to 6.6). FLT3 molecular response (< 10 −2 ) was achieved in 60% of evaluable mCRc patients (n = 15 of 25). The median overall survival for FLT3 mut patients was 10.0 months. CONCLUSION The combination of venetoclax and gilteritinib was associated with high mCRc and FLT3 molecular response rates regardless of prior FLT3 inhibitor exposure. Dose interruptions were needed to mitigate myelosuppression.
Sex and Gender Health Educational Tenets: A Report from the 2020 Sex and Gender Health Education Summit
Kling, Juliana M. , Sleeper, Rebecca B. , Chin, Eliza Lo, Rojek, Mary K., McGregor, Alyson J. , Mitchell, Ann Bradley, Stasiuk, Christina, Templeton, Kimberly , Prasad, Joanne L., Pfister, Sandra L. , Group, on behalf of the SGHE 2020 Summit Working, Templeton, Kimberly , Pfister, Sandra , Kling, Juliana M , Richards, Lorie Gage , Mitchell, Anne Bradley, Newman, Connie B. , Group, on behalf of the SGHE 2020 Summit Working

Mayo Clinic

Journal of Women's Health | July 18, 2022 | Volume: 31 | Issue: 7 | Pages: 905-910

10.1089/jwh.2022.0222 | PMID 35849755 Get It

Background: Sex as a biological variable and gender as a sociocultural variable influence many health conditions and outcomes. However, they have not been incorporated systematically into education across health professions. Methods: Areas of knowledge and abilities that apply to sex and gender education across health professions were summarized from the 2015 and 2018 Sex and Gender Health Education Summits. Results: Using this summary, draft tenets were developed by facilitated interprofessional discussion groups at the 2020 Summit, and then reviewed, edited, and refined by a writing group who recommended four tenets that health care professionals should be able to do: (1) demonstrate knowledge of sex and gender specific health (SGSH), (2) evaluate literature and the conduct of research for incorporation of sex and gender, (3) incorporate sex and gender considerations into clinical decision making, and (4) demonstrate patient advocacy with respect to sex and gender. Conclusion: These tenets provide the framework for collaborative interprofessional education about SGSH. Individual professions can also use the tenets to develop practice-specific competencies, competency statements, and/or assessment benchmarks within the structures of their respective accrediting bodies to advance the health of women, men, and sex and gender minority persons. Interprofessional collaborations are key for sharing best practices in development, curricular integration, and dissemination.
Thyroid nodule location and the risk of thyroid cancer: What do we know?
Jasim, Sina , Gharib, Hossein

Mayo Clinic

Journal of Diabetes and Endocrine Practice | July 18, 2022 | Volume: 04 | Issue: 04 | Pages: 150-153

10.4103/jdep.jdep_51_21 Get It

Thyroid nodules are common in clinical practice and are routinely evaluated with neck ultrasound. Multiple guidelines rely on sonographic features to assist physicians when deciding if nodules require observation or fine-needle aspiration (FNA). Existing classification systems for risk stratification of thyroid nodules are different but equally accurate. The purpose of this article is to review the significance of thyroid nodule location as an important factor in assessing the risk of malignancy. Several topical issues are addressed. (1) Thyroid nodule location and risk of differentiated thyroid cancer, (2) Thyroid nodule location and risk of nodal metastasis, (3) Thyroid nodule location and surgical approach, (4) Thyroid nodule location and stratifications systems (5) Conclusions and future direction. In conclusion, it is advisable not to reply solely on ultrasound-derived risk levels when evaluating thyroid nodules to determine optimal management including nodule FNA, follow-up or no additional intervention. This is likely because other clinically important features might not be accounted for when using those risk stratification algorithms. There are now reasonable data to suggest thyroid nodule location may be an additional prognostic predictor. In the lack of clear radiologic guidance, clinical judgment remains the main driving factor.
Disparities in Cardiovascular Mortality Between Black and White Adults in the United States, 1999 to 2019
Kyalwazi, Ashley, Loccoh, Eméfah , Brewer, LaPrincess C. , Xu, Jiaman, Song, Yang , Maddox, Karen E. Joynt , Yeh, Robert W. , Wadhera, Rishi K. , Joynt Maddox, Karen E , Yeh, Robert W , Wadhera, Rishi K , Brewer, LaPrincess C , Ofili, Elizabeth

Mayo Clinic

Circulation | July 18, 2022 | Volume: 146 | Issue: 3 | Pages: 211-228

10.1161/circulationaha.122.060199 | PMID 35861764 Get It

Background: Black adults experience a disproportionately higher burden of cardiovascular risk factors and disease in comparison with White adults in the United States. Less is known about how sex-based disparities in cardiovascular mortality between these groups have changed on a national scale over the past 20 years, particularly across geographic determinants of health and residential racial segregation. Methods: We used CDC WONDER (Centers for Disease Control and Prevention’s Wide-Ranging Online Data for Epidemiologic Research) to identify Black and White adults age ≥25 years in the United States from 1999 to 2019. We calculated annual age-adjusted cardiovascular mortality rates (per 100 000) for Black and White women and men, as well as absolute rate differences and rate ratios to compare the mortality gap between these groups. We also examined patterns by US census region, rural versus urban residence, and degree of neighborhood segregation. Results: From 1999 to 2019, age-adjusted mortality rates declined overall for both Black and White adults. There was a decline in age-adjusted cardiovascular mortality among Black (602.1 to 351.8 per 100 000 population) and White women (447.0 to 267.5), and the absolute rate difference (ARD) between these groups decreased over time (1999: ARD, 155.1 [95% CI, 149.9–160.3]; 2019: ARD, 84.3 [95% CI, 81.2–87.4]). These patterns were similar for Black (824.1 to 526.3 per 100 000) and White men (637.5 to 396.0; 1999: ARD, 186.6 [95% CI, 178.6–194.6]; 2019: ARD, 130.3 [95% CI, 125.6–135.0]). Despite this progress, cardiovascular mortality in 2019 was higher for Black women (rate ratio, 1.32 [95% CI, 1.30–1.33])— especially in the younger (age <65 years) subgroup (rate ratio, 2.28 [95% CI, 2.23–2.32])—as well as for Black men (rate ratio, 1.33 [95% CI, 1.32–1.34]), compared with their respective White counterparts. There was regional variation in cardiovascular mortality patterns, and the Black-White gap differed across rural and urban areas. Cardiovascular mortality rates among Black women and men were consistently higher in communities with high levels of racial segregation compared with those with low to moderate levels. Conclusions: During the past 2 decades, age-adjusted cardiovascular mortality declined significantly for Black and White adults in the United States, as did the absolute difference in death rates between these groups. Despite this progress, Black women and men continue to experience higher cardiovascular mortality rates than their White counterparts.
Proximal Scar Progression in Idiopathic Subglottic Stenosis After Wedge Excision: Does it Happen?
Xie, Katherine , Bowen, Andrew J. , Richards, Bradley A. , Aden, Aisha A. , Wiedermann, Joshua P. , Rutt, Amy L. , Vassallo, Robert , Edell, Eric S. , Bayan, Semirra L. , Kasperbauer, Jan L. , Ekbom, Dale C. , Xie, Katherine Z , Bowen, Andrew Jay , Aden, Aisha , Wiedermann, Joshua , Rutt, Amy L. , Vassallo, Robert , Bayan, Semirra

Mayo Clinic

The Laryngoscope | July 18, 2022 | Volume: 133 | Issue: 4 | Pages: 875-882

10.1002/lary.30292 | PMID 35848772 Get It

ObjectiveTo compare the incidence of glottic stenosis in idiopathic subglottic stenosis (iSGS) patients with no prior surgical intervention to those with a history of endoscopic dilation and characterize the incidence of glottic involvement, changes in scar length, and progression of scar toward glottis following laser wedge excision (LWE).MethodsA retrospective review of iSGS patients who underwent LWE between 2002 and 2021 was performed. Patients without prior airway surgery were labeled LWE primary (LWEP) and operative findings for LWEP patients were reviewed for glottic involvement, scar length (DL), and distance from the glottis to superior‐most aspect of scar (DGS). Rates (in mm/procedure) of DΔL, reflecting an increase in length, and D−ΔGS, reflecting proximal migration, were calculated by dividing DΔL and D−ΔGS by the number of LWE procedures.Results213 iSGS patients underwent LWE, with 132 being LWEP patients. LWEP had a lower incidence of baseline glottic involvement (n = 6, 4.5%) than LWE secondary (LWES; n = 6, 7.5%). Four new cases of glottic involvement were noted in LWEP patients following LWE, with only one being clinically significant resulting in permanently decreased vocal fold mobility. With each procedure, scar length increased by 1.0 mm and DGS decreased by 0.7 mm, reflecting a migration or decrease in DGS of 9.5% with each procedure with respect to initial DGS. Overall rates of glottic stenosis following operations were similar between LWEP and LWES cohorts, 7.6% and 7.5% respectively.ConclusionThere appears to be a low risk of glottic involvement resulting from the LWE procedure in iSGS patients.Level of Evidence4 Laryngoscope, 133:875–882, 2023